Treatment includes patients with relapsed or refractory multiple myeloma
Takeda announced that the National Institutes of Health (NICE) has recommended NINLARO in combination with lenalidomide and dexamethasone.
Also known as ixazomib, this therapy is an option for the treatment of relapsed or refractory multiple myeloma (RRMM) in adult patients who have received 2 or 3 treatments.
Multiple myeloma is a rare, life-threatening blood cancer that arises from plasma cells (a type of white blood cell made in the bone marrow). Approximately 6,000 people in the UK are diagnosed with multiple myeloma each year and approximately 24,000 people in the UK have multiple myeloma.
Ixazomib is the only oral proteasome inhibitor approved in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. Recommendations from NICE follow results from the Phase 3 TOURMALINE-MM1 trial.
Meanwhile, the treatment has been available through the Cancer Drugs Fund since late 2017 for patients already on two or three treatments. To date, in the UK alone he has been used to treat over 4,000 patients.
Professor Graham Jackson, Consultant Hematologist at Freeman Hospital, Newcastle-upon-Tyne Hospital NHS Trust, commented:
Dr Emma Roffe, Country Head of Oncology UK and Ireland, Takeda UK, explains: The results announced today reflect the long-standing perseverance, dedication and passion of Takeda, the clinical and patient community to ensure patients maintain access to the established standard of care in RRMM. “
“Launched in 2016, this evaluation is a true demonstration of Takeda’s patient-first mindset and our commitment to improving patients’ lives.”
